Clinical studies have shown that it is equally effective in daily therapy in the control of blood sugar, but with less risk of hypoglycaemias in patients with type 2 diabetes
A single injection per week instead of one a day: the new frontier of insulin therapy for type 1 and type 2 diabetes arrives in Italy, First country in Europe to make it available and refundable After the green light of Aifa, the Italian drug agency.
The new insulin reduces annual injections from 365 to 52
–
This epochal change for millions of people with diabetes, 1.3 million according to the most recent estimates, is possible thanks to ICODECthe first insulin with a weekly administration developed by Novo Nordisk that reduces the need for 365 to only 52 injections per yearone per week and no longer one a day.
A real revolution in the treatment of diabetes for over a century, as underlined by Riccardo Candidopresident of the Medici Diabetologi Association. One hundred years after the discovery of insulin, the European drug agency has given the green light to its most modern form, capable of guaranteeing a prolonged and stable release of the drug.
How the new insulin works
–
The molecule ICODEC It is a modified insulin, designed to remain active in the body up to eight days thanks to a link with the albumin. This structure slows down the release of the hormone and maintains a stable concentration in the blood, avoiding blood sugar changes. Onward clinical studies have shown that it is equally effective of daily therapy in the control of blood sugarbut with less risk of hypoglycaemias in patients with type 2 diabetes.
According to the evidence available today, ICODEC And Ideal for adults with type 2 diabetes which, despite the use of drugs such as metformin, glyphlozine or agonists of the GLP-1, do not reach good glycemic control. For now Use in children is not foreseenwhile for patients with type 1 diabetes the indication is limited to specific cases selected.
The concrete benefits for patients and for the health system
–
Go from a daily administration to a weekly significantly reduces the psychological and practical load of therapyespecially for the elderly or fragile patients followed by caregiver. Less injections also mean less errors, More therapeutic continuity and minor sanitary wastewith tangible environmental benefits.
The Undersecretary of Health Marcello Gemmato He defined this turning point “concrete progress, the result of the collaboration between institutions, industry and scientific community”. And the President of the Italian Society of Diabetology, Raffaella Buzzettihas launched an appeal to guarantee fair access to the new therapy throughout the national territory.
When will it be available in Italy?
–
Italy is already ready to adopt this innovative insulin on a large scale, even if in this phase Its reimbursed availability is limited to some regions of the country. The goal of the Italian health authorities is to extend the treatment to as many patients as possible during this 2025reaching even the less covered areas.
© RESERVED REPRODUCTION